Patents by Inventor Kohei SOEDA

Kohei SOEDA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR PREPARING ANTIBODY-CONTAINING FORMULATION
    Publication number: 20260022194
    Abstract: Provided is a pharmaceutical formulation with reduced particle formation, comprising an anti-coagulation factor IXa/X antibody (bispecific monoclonal antibody) that substitutes for coagulation factor VIII, or an anti-IL-6 receptor antibody that inhibits binding to the interleukin 6 receptor. Provided is a pharmaceutical formulation comprising an aqueous solution comprising a polyoxyethylene polyoxypropylene glycol (poloxamer), wherein the poloxamer is represented by formula I: wherein a and c are independently an integer selected from 75 to 85; b is an integer selected from 22 to 33; and a, b and c are average values over the entire poloxamer, and, the poloxamer comprises poloxamer molecules comprising 34 or more (C3H6O) in the molecule at a ratio of 3% (w/w) or more of the total poloxamer.
    Type: Application
    Filed: October 6, 2025
    Publication date: January 22, 2026
    Applicants: Chugai Seiyaku Kabushiki Kaisha, Hoffmann-La Roche Inc.
    Inventors: Kohei SOEDA, Masakazu FUKUDA, Masaya TAKAHASHI, Hirotaka IMAI, Satoshi SAITOH, Jeremy DUBOEUF, Kishore RAVURI, Robert KOPF, Wei CHEN, Nuria Sancho OLTRA
  • Pharmaceutical formulation comprising aqueous solution of antibody
    Patent number: 12460015
    Abstract: Provided is a pharmaceutical formulation with reduced particle formation, comprising an anti-coagulation factor IXa/X antibody (bispecific monoclonal antibody) that substitutes for coagulation factor VIII, or an anti-IL-6 receptor antibody that inhibits binding to the interleukin 6 receptor. Provided is a pharmaceutical formulation comprising an aqueous solution comprising a polyoxyethylene polyoxypropylene glycol (poloxamer), wherein the poloxamer is represented by formula I: HO(C2H4O)a(C3H6O)b(C2H4O)cH??(I) wherein a and c are independently an integer selected from 75 to 85; b is an integer selected from 22 to 33; and a, b and c are average values over the entire poloxamer, and, the poloxamer comprises poloxamer molecules comprising 34 or more (C3H6O) in the molecule at a ratio of 3% (w/w) or more of the total poloxamer.
    Type: Grant
    Filed: December 1, 2022
    Date of Patent: November 4, 2025
    Assignees: Chugai Seiyaku Kabushiki Kaisha, Hoffmann-La Roche Inc.
    Inventors: Kohei Soeda, Masakazu Fukuda, Masaya Takahashi, Hirotaka Imai, Satoshi Saitoh, Jeremy Duboeuf, Kishore Ravuri, Robert Kopf, Wei Chen, Nuria Sancho Oltra
  • METHOD FOR PREPARING ANTIBODY-CONTAINING FORMULATION
    Publication number: 20250136716
    Abstract: Provided is a pharmaceutical formulation with reduced particle formation, comprising an anti-coagulation factor IXa/X antibody (bispecific monoclonal antibody) that substitutes for coagulation factor VIII, or an anti-IL-6 receptor antibody that inhibits binding to the interleukin 6 receptor. Provided is a pharmaceutical formulation comprising an aqueous solution comprising a polyoxyethylene polyoxypropylene glycol (poloxamer), wherein the poloxamer is represented by formula I: HO(C2H4O)a(C3H6O)b(C2H4O)cH??(I) wherein a and c are independently an integer selected from 75 to 85; b is an integer selected from 22 to 33; and a, b and c are average values over the entire poloxamer, and, the poloxamer comprises poloxamer molecules comprising 34 or more (C3H6O) in the molecule at a ratio of 3% (w/w) or more of the total poloxamer.
    Type: Application
    Filed: December 1, 2022
    Publication date: May 1, 2025
    Applicants: Chugai Seiyaku Kabushiki Kaisha, Hoffmann-La Roche Inc.
    Inventors: Kohei SOEDA, Masakazu FUKUDA, Masaya TAKAHASHI, Hirotaka IMAI, Satoshi SAITOH, Jeremy DUBOEUF, Kishore RAVURI, Robert KOPF, Wei CHEN, Nuria Sancho OLTRA